{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hepatitis-b/background-information/prevalence/","result":{"pageContext":{"chapter":{"id":"e06f78dc-080c-542f-b450-356db08c00a9","slug":"prevalence","fullItemName":"Prevalence","depth":2,"htmlHeader":"<!-- begin field 23e4a57b-1d01-431e-8006-6e40d45e0133 --><h2>How common is it?</h2><!-- end field 23e4a57b-1d01-431e-8006-6e40d45e0133 -->","summary":"","htmlStringContent":"<!-- begin item 03476142-3bea-4f6c-bb98-6c66bb335320 --><!-- begin field b0ac7549-9b3a-4b88-b2cc-e13e1707e7ed --><ul><li>The UK is a very low incidence and prevalence country for hepatitis B. In England in 2018, a total of 381 acute or probable acute cases of hepatitis B were reported. This equates to an annual incidence of 0.68 per 100,000 population.</li><li>Approximately 180,000 people are thought to have chronic hepatitis B infection in the UK, an overall prevalence of 0.3%.</li><li>Worldwide, around 240 million people have chronic hepatitis B:<ul><li>In regions with high prevalence, more than 8% of the population have chronic hepatitis B infection (for example Southeast Asia [excluding Japan], China, and sub-Saharan Africa).</li><li>In the UK, the prevalence of positivity to hepatitis B surface antigen (HBsAg) is highest in those people who were born in countries with endemic infection. Several thousand people with chronic hepatitis B are estimated to come to the UK each year from endemic areas, but they often do not present until the disease is advanced or they become pregnant.</li></ul></li><li>The prevalence of people with antibodies to hepatitis B core antigen (anti-HBc) — a marker of current or previous infection (seroprevalence) — is less than 2% in the UK. In parts of China and South Korea, the seroprevalence is 96%.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">Sundaram and Kowdley, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">British Liver Trust, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">PHE, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">BMJ Best Practice, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">NaTHNac, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">PHE, 2019b</a>]</p><!-- end field b0ac7549-9b3a-4b88-b2cc-e13e1707e7ed --><!-- end item 03476142-3bea-4f6c-bb98-6c66bb335320 -->","topic":{"id":"f75dcfde-3cb4-5059-94df-19d53a6c28e9","topicId":"4fc86266-0752-4667-994f-7f6fc7e46056","topicName":"Hepatitis B","slug":"hepatitis-b","lastRevised":"Last revised in November 2019","chapters":[{"id":"986057cd-07a1-565e-9c7a-d3b3dc88368d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2331f5c5-fb51-54d1-b722-946b4f34a693","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"653459fe-510a-5a1a-92dc-8197c598c85e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"12e8fb8c-9424-5f20-90e5-65e823f603c3","slug":"changes","fullItemName":"Changes"},{"id":"2299e2ba-3fb3-5f37-9c6b-63ec8dbbffd6","slug":"update","fullItemName":"Update"}]},{"id":"c14d3383-629b-5bd6-b6c0-318bbcf86fb2","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"58e5cd67-9ca7-5bfe-b2b6-bf4372ac895f","slug":"goals","fullItemName":"Goals"},{"id":"a1abbdfd-238b-55b7-8de2-09fd4ff6065b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fc44420e-13ab-526e-a0c7-ef2f93cce77b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b59d4642-5914-585b-82b1-6f7989cef100","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"af246587-2615-513e-aafc-3ea762d8aab7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bba17b9f-47f8-52cf-a8e7-111c1a5094a2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2c6fa000-50a2-5823-9acb-0bd808dc51e6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"dfcb6ed4-783a-5fbc-9259-096762bb7c69","slug":"definition","fullItemName":"Definition"},{"id":"e06f78dc-080c-542f-b450-356db08c00a9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0c1d15cf-36ee-5c84-ad7c-e06836a161c0","slug":"transmission","fullItemName":"Transmission"},{"id":"939f1d6a-6b15-5c4f-91c8-9164e800cd87","slug":"people-at-high-risk-of-hepatitis-b","fullItemName":"People at high risk of hepatitis B"},{"id":"d452f04a-7d9d-5739-9cb9-f583eb136f3a","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"b3642d36-7175-548b-b6f0-d694e7397bd3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6acbd5e1-b0e6-527b-bad0-42c21a928d1e","slug":"when-to-test-for-hepatitis-b","fullItemName":"When to test for hepatitis B"},{"id":"706362c9-e255-511b-83b4-74b853c926c7","slug":"how-to-test-for-hepatitis-b","fullItemName":"How to test for hepatitis B"},{"id":"c0c1ae56-2316-56eb-ad65-4b85e982fc11","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"41c2681f-bf40-5b08-a518-32f2ab1206fb","fullItemName":"Management","slug":"management","subChapters":[{"id":"b2d949a2-a42f-5c0a-a955-414bac741bd3","slug":"prevention-of-infection-with-hepatitis-b","fullItemName":"Scenario: Prevention of infection with Hepatitis B"},{"id":"00ed825c-5927-50f5-940d-94d6b4001150","slug":"managing-hepatitis-b-infection","fullItemName":"Scenario: Managing hepatitis B infection"}]},{"id":"c7941282-a3b2-5716-b0cc-80cb243a7405","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8df28bde-0bc5-533e-a54b-507fd3ceee61","slug":"hepatitis-b-vaccine","fullItemName":"Hepatitis B vaccine"},{"id":"c7099851-c102-56f2-b063-021f3d00b880","slug":"analgesics","fullItemName":"Analgesics"},{"id":"6a9675fd-5496-5ca4-9a76-36ee6cc93a25","slug":"anti-emetics","fullItemName":"Anti-emetics"},{"id":"1576eb24-e96c-50e6-9976-05164be1127e","slug":"anti-pruritics","fullItemName":"Anti-pruritics"}]},{"id":"3c7651c1-b246-51db-85b3-e1b6713a47bd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"548463b9-9c49-5154-bad9-fe10668804da","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8b3032fc-e20a-509b-b390-81cef2509ded","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5e0cdb38-e518-5a0c-9215-493c78f74377","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3e63144c-a0f3-5eb1-980d-a219e8a53633","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"94d851c4-3314-5a3d-801a-0a208e287514","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4df2edc1-d17c-57d1-a914-4100299c8f7d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cecf6c0b-d134-54cb-abef-c2ccab9effb6","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2c6fa000-50a2-5823-9acb-0bd808dc51e6","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}